Biotech and Pharma

Nuvation Bio and Ardelyx have both seen shares continue slumping in 2025. Insiders at both biotechs have bought stock.

In a series of votes Thursday, the CDC’s vaccine committee voted against the use of thimerosal, an ingredient that has long been the focus of antivaccine advocates.

Micron beats expectations on demand for AI memory chips, BP stock whipsaws on report Shell approached it about a deal, and more news to start your day.

The health secretary handpicked the new vaccine advisers just days after firing all 17 of the committee’s previous members.

Robert F. Kennedy Jr. is a longtime skeptic of vaccines and is changing how the government regulates them.

Iran, Israel cease-fire gets off to a fragile start, Compass sues Zillow in real estate rift, nuclear firm Holtec could go public, and more news to start your day.

Tesla shares rise sharply after the electric-vehicle company launched its highly anticipated robo-taxi service in Austin, Texas, on Sunday.

The maker of Ozempic and Wegovy faces stiff competition in the weight-loss drug market.

At the highest dosage of MariTide, 27% of patients stopped the drug due to a gastrointestinal adverse event.

Novo Nordisk accuses the telehealth company of breaking a law related to drug compounding.

John Paulson, former hedge-fund manager, bought large blocks of Bausch Health and Perpetua Resources through funds.

The HHS said center directors deserve to be supported by managers aligned with aggressive goals “to expeditiously advance therapeutics for rare diseases using the gold standard of science.”

Five years ago, scientists and investors were excited about gene therapy offering one-and-done cures for deadly diseases. Today, much of the enthusiasm has dried up.

Under CEO Dave Ricks, Eli Lilly has won the war of the weight-loss drugs.

The drug, called Yeztugo, could represent a major development in prevention.

Solar stocks drop sharply as Senate Republicans detail changes to Trump’s tax-and-spending bill that would phase out solar, wind and energy tax credits by 2028.

Lilly confirmed it would buy a Boston-based clinical-stage company developing genetic medicines for cardiovascular disease.

Sarepta Therapeutics falls sharply after suspending shipments of Elevidys for infusions in non-ambulatory patients because of the death of a second patient from acute liver failure.

The deal is worth an initial $561 million, with potential for $234 million in add-ons.

A second patient receiving its experimental gene therapy Elevidys has died from liver failure, raising serious questions on the drug’s outlook.

The Danish drug maker is being more forceful since its CEO departed last month.  

The health secretary fired all the members of the Advisory Committee on Immunization Practices late on Monday.

CureVac stock soared 32% in early trading.

The president wants a the most-favored-nation pricing model. But the U.S. drug industry is offering a host of reasons why that isn’t a good idea.

There are two weeks to go until the panel’s next scheduled meeting. As of Wednesday morning, the committee has no known members.